#AlzeCure #AlzeCurePharma #pain #paintherapy #ACD440 #NeuPSIG2025 #neuropathicpain #peripheralneuropathicpain #TRPV1antagonist #heatinducedpain #strategicinlicensing #inlicensing #painrelief #painkillers #opioidcrisis #painprecisionmedicine #chronicneuropathicpain
pharmatimes.com/news/alzecur...
pharmatimes.com/news/alzecur...
AlzeCure to present promising pain therapy ACD440 at NeuPSIG 2025 - PharmaTimes
Clinical results from phase 2 study highlight analgesic effects in neuropathic pain patients
pharmatimes.com
September 2, 2025 at 8:28 AM
#SenjuPharma has launched a new drug for #dryeyedisease (DED) in #Japan, #Avarept, which is the first drug in the #TRPV1antagonist class to reach the market.
Senju launches first-in-class dry eye disease drug in Japan
Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.
buff.ly
April 10, 2026 at 3:31 PM
#SenjuPharma has launched a new drug for #dryeyedisease (DED) in #Japan, #Avarept, which is the first drug in the #TRPV1antagonist class to reach the market.